Given that there is no preventative treatment for OM in the entire world, and not even a good treatment (standard care more palliative in nature comparable in pain reduction and efficacy to ice cubes), and given that with near certainty most of the countless millions of patients undergoing chemotherapy and radiation therapy will get a level of OM, and given that they spread in efficacy between placebo in the powered phase 2 trial’s interim results was mind-boggling, on what basis do you stand on to now think that the topline data and the trial will fail, and further, given your obvious expertise, how would you define success (at which levels active vs placebo) for topline.